The Evaluation of Efficacy and Safety of Rituximab in Refractory CIDP Patients With IgG4 Autoantibodies (RECIPE)
The Evaluation of Efficacy and Safety of Rituximab (Genetical Recombination) in Refractory Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Patients With Immunoglobulin G4 (IgG4) Autoantibodies in the Exploratory Clinical Trial
Sponsor: Japan Agency for Medical Research and Development
Listed as NCT03864185, this PHASE2 trial focuses on Chronic Inflammatory Demyelinating Polyradiculoneuropathy (CIDP) and remains completed. Sponsored by Japan Agency for Medical Research and Development, it has been updated 8 times since 2019, reflecting limited change activity. This study adds to the evidence base for this therapeutic area through structured, versioned documentation.
Status Flow
Change History
8 versions recorded-
Sep 2024 — Present [monthly]
Completed PHASE2
-
Jul 2024 — Sep 2024 [monthly]
Completed PHASE2
-
Sep 2021 — Jul 2024 [monthly]
Completed PHASE2
Status: Active Not Recruiting → Completed
-
Jan 2021 — Sep 2021 [monthly]
Active Not Recruiting PHASE2
-
Jul 2020 — Jan 2021 [monthly]
Active Not Recruiting PHASE2
Status: Recruiting → Active Not Recruiting
▶ Show 3 earlier versions
-
Jan 2020 — Jul 2020 [monthly]
Recruiting PHASE2
-
Aug 2019 — Jan 2020 [monthly]
Recruiting PHASE2
-
Apr 2019 — Aug 2019 [monthly]
Recruiting PHASE2
First recorded
Mar 2019
Trial started
Per CT.gov start date — pre-dates our first snapshot
Eligibility Summary
No eligibility information available.
Contact Information
- Japan Agency for Medical Research and Development
- Nagoya University
- Zenyaku Kogyo Co., Ltd.
For direct contact, visit the study record on ClinicalTrials.gov .